20 results on '"Eickhardt‐Dalbøge, Christina Schjellerup"'
Search Results
2. The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment
- Author
-
Eickhardt-Dalbøge, Christina Schjellerup, Ingham, Anna Cäcilia, Andersen, Lee O'Brien, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Ellervik, Christina, Olsen, Lars Rønn, Hasselbalch, Hans Carl, Nielsen, Xiaohui Chen, and Christensen, Jens Jørgen Elmer
- Published
- 2023
- Full Text
- View/download PDF
3. Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms
- Author
-
Boklund, Tobias Idor, primary, Snyder, Jordan, additional, Gudmand-Hoeyer, Johanne, additional, Larsen, Morten Kranker, additional, Knudsen, Trine Alma, additional, Eickhardt-Dalbøge, Christina Schjellerup, additional, Skov, Vibe, additional, Kjær, Lasse, additional, Hasselbalch, Hans C., additional, Andersen, Morten, additional, Ottesen, Johnny T., additional, and Stiehl, Thomas, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study
- Author
-
Larsen, Morten Kranker, Skov, Vibe, Kjær, Lasse, Eickhardt-Dalbøge, Christina Schjellerup, Knudsen, Trine Alma, Kristiansen, Marie Hvelplund, Sørensen, Anders Lindholm, Wienecke, Troels, Andersen, Morten, Ottesen, Johnny T., Gudmand-Høyer, Johanne, Snyder, Jordan Andrew, Andersen, Mikkel Porsborg, Torp-Pedersen, Christian, Poulsen, Henrik Enghusen, Stiehl, Thomas, Hasselbalch, Hans Carl, Ellervik, Christina, Larsen, Morten Kranker, Skov, Vibe, Kjær, Lasse, Eickhardt-Dalbøge, Christina Schjellerup, Knudsen, Trine Alma, Kristiansen, Marie Hvelplund, Sørensen, Anders Lindholm, Wienecke, Troels, Andersen, Morten, Ottesen, Johnny T., Gudmand-Høyer, Johanne, Snyder, Jordan Andrew, Andersen, Mikkel Porsborg, Torp-Pedersen, Christian, Poulsen, Henrik Enghusen, Stiehl, Thomas, Hasselbalch, Hans Carl, and Ellervik, Christina
- Abstract
The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1–1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03–2.09) for the whole population and 2.93(2.44–3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71–2.69), 2.19(1.89–2.54), and 2.31(1.91–2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(pinteraction < 2×10–16), with a HR for NLR ≥ 6 of 2.23(2.17–2.29), 4.10(4.01–4.20), and 7.69(7.50–7.89), for CCI-score 0, 1–2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF., The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1-1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03-2.09) for the whole population and 2.93(2.44-3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71-2.69), 2.19(1.89-2.54), and 2.31(1.91-2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(pinteraction < 2×10-16), with a HR for NLR ≥ 6 of 2.23(2.17-2.29), 4.10(4.01-4.20), and 7.69(7.50-7.89), for CCI-score 0, 1-2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF.
- Published
- 2024
5. JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms
- Author
-
Eickhardt-Dalbøge, Christina Schjellerup, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Andersen, Lee O’Brien, Lilje, Berit, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Sørensen, Anders Lindholm, Ellervik, Christina, Olsen, Lars Rønn, Christensen, Jens Jørgen Elmer, Nielsen, Xiaohui Chen, Hasselbalch, Hans Carl, Ingham, Anna Cäcilia, Eickhardt-Dalbøge, Christina Schjellerup, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Andersen, Lee O’Brien, Lilje, Berit, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Sørensen, Anders Lindholm, Ellervik, Christina, Olsen, Lars Rønn, Christensen, Jens Jørgen Elmer, Nielsen, Xiaohui Chen, Hasselbalch, Hans Carl, and Ingham, Anna Cäcilia
- Abstract
Background Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis. Methods We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation. Results MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p = .003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p < .001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation. Conclusion The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more., Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis. Methods: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation. Results: MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p =.003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p <.001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation. Conclusion: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.
- Published
- 2024
6. JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.
- Author
-
Eickhardt‐Dalbøge, Christina Schjellerup, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Andersen, Lee O' Brien, Lilje, Berit, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Sørensen, Anders Lindholm, Ellervik, Christina, Olsen, Lars Rønn, Christensen, Jens Jørgen Elmer, Nielsen, Xiaohui Chen, Hasselbalch, Hans Carl, and Ingham, Anna Cäcilia
- Subjects
- *
GUT microbiome , *MYELOPROLIFERATIVE neoplasms , *MYELOFIBROSIS , *POLYCYTHEMIA vera , *NUCLEOTIDE sequencing , *INFECTION control - Abstract
Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady‐state hematopoiesis. Methods: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next‐generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre‐MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub‐diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub‐diagnoses and MPN mutation. Results: MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p =.003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p <.001). The microbiota of CALR‐positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F‐positive patients, only minor differences in the gut microbiota were observed between MPN sub‐diagnoses, illustrating the importance of this mutation. Conclusion: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Pronounced gut microbiota signatures in patients with JAK2V617F- positive essential thrombocythemia
- Author
-
Eickhardt-Dalbøge, Christina Schjellerup, primary, Ingham, Anna Cäcilia, additional, Nielsen, Henrik V., additional, Fuursted, Kurt, additional, Stensvold, Christen Rune, additional, Andersen, Lee O'Brien, additional, Larsen, Morten Kranker, additional, Kjær, Lasse, additional, Christensen, Sarah Friis, additional, Knudsen, Trine Alma, additional, Skov, Vibe, additional, Ellervik, Christina, additional, Olsen, Lars Rønn, additional, Hasselbalch, Hans Carl, additional, Elmer Christensen, Jens Jørgen, additional, and Nielsen, Xiaohui Chen, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial
- Author
-
Knudsen, Trine A., Hansen, Dennis Lund, Ocias, Lukas Frans, Bjerrum, Ole Weis, Brabrand, Mette, Christensen, Sarah F., Eickhardt-Dalbøge, Christina Schjellerup S., Ellervik, Christina, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Larsen, Morten Kranker, Mourits-Andersen, Torben, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Sørensen, Anders Lindholm, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas S., and Hasselbalch, Hans Carl
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
9. Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
- Author
-
Eickhardt-Dalbøge, Christina Schjellerup, Ingham, Anna Cäcilia, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Andersen, Lee O.Brien, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Ellervik, Christina, Olsen, Lars Rønn, Hasselbalch, Hans Carl, Christensen, Jens Jørgen Elmer, Nielsen, Xiaohui Chen, Eickhardt-Dalbøge, Christina Schjellerup, Ingham, Anna Cäcilia, Nielsen, Henrik V., Fuursted, Kurt, Stensvold, Christen Rune, Andersen, Lee O.Brien, Larsen, Morten Kranker, Kjær, Lasse, Christensen, Sarah Friis, Knudsen, Trine Alma, Skov, Vibe, Ellervik, Christina, Olsen, Lars Rønn, Hasselbalch, Hans Carl, Christensen, Jens Jørgen Elmer, and Nielsen, Xiaohui Chen
- Abstract
Essential thrombocythemia (ET) is part of the Philadelphia chromosome-negative myeloproliferative neoplasms. It is characterized by an increased risk of thromboembolic events and also to a certain degree hypermetabolic symptoms. The gut microbiota is an important initiator of hematopoiesis and regulation of the immune system, but in patients with ET, where inflammation is a hallmark of the disease, it is vastly unexplored. In this study, we compared the gut microbiota via amplicon-based 16S rRNA gene sequencing of the V3–V4 region in 54 patients with ET according to mutation status Janus-kinase 2 (JAK2V617F)-positive vs JAK2V617F-negative patients with ET, and in 42 healthy controls (HCs). Gut microbiota richness was higher in patients with ET (median-observed richness, 283.5; range, 75–535) compared with HCs (median-observed richness, 191.5; range, 111–300; P < 0.001). Patients with ET had a different overall bacterial composition (beta diversity) than HCs (analysis of similarities [ANOSIM]; R = 0.063, P = 0.004). Patients with ET had a significantly lower relative abundance of taxa within the Firmicutes phylum compared with HCs (51% vs 59%, P = 0.03), and within that phylum, patients with ET also had a lower relative abundance of the genus Faecalibacterium (8% vs 15%, P < 0.001), an important immunoregulative bacterium. The microbiota signatures were more pronounced in patients harboring the JAK2V617F mutation, and highly similar to patients with polycythemia vera as previously described. These findings suggest that patients with ET may have an altered immune regulation; however, whether this dysregulation is induced in part by, or is itself inducing, an altered gut microbiota remains to be investigated. IMPORTANCE Essential thrombocythemia (ET) is a cancer characterized by thrombocyte overproduction. Inflammation has been shown to be vital in both the initiation and progression of other myeloproliferative neoplasms, and it is well known that the gut micr
- Published
- 2023
10. Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera
- Author
-
Sørensen, Anders Lindholm Lindholm, primary, Skov, Vibe, additional, Kjær, Lasse, additional, Eickhardt-Dalbøge, Christina Schjellerup Schjellerup, additional, Larsen, Morten Kranker, additional, Nielsen, Claus, additional, Thomsen, Carsten, additional, Gjerdrum, Lise Mette Rahbek, additional, Knudsen, Trine Alma, additional, Ellervik, Christina, additional, Overgaard, Ulrik Malthe, additional, Andersen, Christen Lykkegaard, additional, Bjørn, Mads Emil, additional, and Hasselbalch, Hans Carl, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Patients with Essential Thrombocythemia Have a Gut Microbiota That Differs from Healthy Controls
- Author
-
Eickhardt-Dalbøge, Christina Schjellerup Schjellerup, primary, Ingham, Anna Cäcilia, additional, Andersen, Lee O'Brien, additional, Nielsen, Henrik V, additional, Fuursted, Kurt, additional, Stensvold, Christen Rune, additional, Larsen, Morten Kranker, additional, Kjær, Lasse, additional, Christensen, Sarah F., additional, Knudsen, Trine A., additional, Skov, Vibe, additional, Ellervik, Christina, additional, Olsen, Lars Rønn, additional, Hasselbalch, Hans Carl, additional, Nielsen, Xiaohui Chen, additional, and Christensen, Jens Jørgen Elmer, additional
- Published
- 2022
- Full Text
- View/download PDF
12. The Gut Microbiota in Patients with Polycythemia Vera is Distinct from that of Healthy Controls and Varies by Treatment
- Author
-
Eickhardt-Dalbøge, Christina Schjellerup, primary, Ingham, Anna Cäcilia, additional, Andersen, Lee O'Brien, additional, Nielsen, Henrik Vedel, additional, Fuursted, Kurt, additional, Stensvold, Christen Rune, additional, Larsen, Morten Kranker, additional, Kjær, Lasse, additional, Christensen, Sarah Friis, additional, Knudsen, Trine Alma, additional, Skov, Vibe, additional, Ellervik, Christina, additional, Olsen, Lars Rønn, additional, Hasselbalch, Hans Carl, additional, Nielsen, Xiaohui Chen, additional, and Christensen, Jens Jørgen Elmer, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up
- Author
-
Larsen, Morten K., primary, Skov, Vibe, additional, Kjær, Lasse, additional, Møller‐Palacino, Natascha A., additional, Pedersen, Rasmus K., additional, Andersen, Morten, additional, Ottesen, Johnny T., additional, Cordua, Sabrina, additional, Poulsen, Henrik E., additional, Dahl, Morten, additional, Knudsen, Trine A., additional, Eickhardt‐Dalbøge, Christina Schjellerup, additional, Koschmieder, Steffen, additional, Pedersen, Kasper M., additional, Çolak, Yunus, additional, Bojesen, Stig E., additional, Nordestgaard, Børge G., additional, Stiehl, Thomas, additional, Hasselbalch, Hans C., additional, and Ellervik, Christina, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis.
- Author
-
Kjær, Lasse, Skov, Vibe, Larsen, Morten Kranker, Boklund, Tobias Idor, Andersen, Morten, Kefala, Maria, Knudsen, Trine A., Eickhardt-Dalbøge, Christina Schjellerup, Stiehl, Thomas, Gudmand-Høyer, Johanne, Snyder, Jordan, Holmström, Morten, Andersen, Mads H., Ottesen, Johnny T., Ellervik, Christina, and Hasselbalch, Hans C.
- Subjects
MYELOFIBROSIS ,HEMATOPOIESIS ,BLOOD cell count ,THROMBOPOIETIN receptors ,MYELOPROLIFERATIVE neoplasms ,SYMPTOMS - Abstract
Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated individual during a 12 year follow-up from initial identification of CALR clonal hematopoiesis of indeterminate potential (CHIP) to the diagnosis of pre-MF. The pre-diagnostic exponential development dynamics of the malignant clone demonstrated close correlation with the platelet counts, neutrophil-to-lymphocyte (NLR) ratio, and inversely correlated to hemoglobin and erythrocyte counts. Backward extrapolation of the growth rate indicated the potential for discovery of the malignant clone many years prior to presentation of overt disease, opening a window of opportunity for early treatment intervention. We did not find any additional mutations associated with MPNs and the current case report provides novel information regarding the development of a driver mutation and the association with blood cell counts prior to clinical manifestation of symptoms suggesting that pre-diagnostic dynamics may supplement future diagnostic criteria for early diagnosis and intervention in MPN patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow-up
- Author
-
Larsen, Morten K., Skov, Vibe, Kjær, Lasse, Møller-Palacino, Natascha A., Pedersen, Rasmus K., Andersen, Morten, Ottesen, Johnny T., Cordua, Sabrina, Poulsen, Henrik E., Dahl, Morten, Knudsen, Trine A., Eickhardt-Dalbøge, Christina Schjellerup, Koschmieder, Steffen, Pedersen, Kasper M., Çolak, Yunus, Bojesen, Stig E., Nordestgaard, Børge G., Stiehl, Thomas, Hasselbalch, Hans C., Ellervik, Christina, Larsen, Morten K., Skov, Vibe, Kjær, Lasse, Møller-Palacino, Natascha A., Pedersen, Rasmus K., Andersen, Morten, Ottesen, Johnny T., Cordua, Sabrina, Poulsen, Henrik E., Dahl, Morten, Knudsen, Trine A., Eickhardt-Dalbøge, Christina Schjellerup, Koschmieder, Steffen, Pedersen, Kasper M., Çolak, Yunus, Bojesen, Stig E., Nordestgaard, Børge G., Stiehl, Thomas, Hasselbalch, Hans C., and Ellervik, Christina
- Abstract
The myeloproliferative neoplasms are associated with chronic kidney disease but whether clonal haematopoiesis of indeterminate potential (CHIP) is associated with impaired kidney function is unknown. In the Danish General Suburban Population Study (N = 19 958) from 2010 to 2013, 645 individuals were positive for JAK2V617F (N = 613) or CALR (N = 32) mutations. Mutation-positive individuals without haematological malignancy were defined as having CHIP (N = 629). We used multiple and inverse probability weighted (IPW)-adjusted linear regression analysis to estimate adjusted mean (95% confidence interval) differences in estimated glomerular filtration rate (eGFR; ml/min/1.73 m2) by mutation status, variant allele frequency (VAF%), blood cell counts, and neutrophil-to-lymphocyte ratio (NLR). We performed 11-year longitudinal follow-up of eGFR in all individuals. Compared to CHIP-negative individuals, the mean differences in eGFR were −5.6 (−10.3, −0.8, p =.02) for CALR, −11.9 (−21.4, −2.4, p = 0.01) for CALR type 2, and −10.1 (−18.1, −2.2, p =.01) for CALR with VAF ≥ 1%. The IPW-adjusted linear regression analyses showed similar results. NLR was negatively associated with eGFR. Individuals with CALR type 2 had a worse 11-year longitudinal follow-up on eGFR compared to CHIP-negative individuals (p =.004). In conclusion, individuals with CALR mutations, especially CALR type 2, had impaired kidney function compared to CHIP-negative individuals as measured by a lower eGFR at baseline and during 11-year follow-up.
- Published
- 2022
16. The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients
- Author
-
Skov, Vibe, primary, Sørensen, Anders Lindholm, additional, Knudsen, Trine Alma, additional, Bjørn, Mads Emil, additional, Ellervik, Christina, additional, Kranker Larsen, Morten, additional, Eickhardt-Dalbøge, Christina Schjellerup Schjellerup, additional, Christensen, Sarah Friis, additional, Thomassen, Mads, additional, Kruse, Torben A, additional, and Hasselbalch, Hans C., additional
- Published
- 2021
- Full Text
- View/download PDF
17. The Gut Microbiota in Patients with Polycythemia Vera: Novel Vs. Conventional Treatments
- Author
-
Eickhardt-Dalbøge, Christina Schjellerup Schjellerup, primary, Ingham, Anna Cäcilia, additional, Andersen, Lee O'Brien, additional, Nielsen, Henrik V, additional, Fuursted, Kurt, additional, Larsen, Morten Kranker, additional, Kjær, Lasse, additional, Christensen, Sarah Friis, additional, Knudsen, Trine Alma, additional, Skov, Vibe, additional, Ellervik, Christina, additional, Hasselbalch, Hans C., additional, Christensen, Jens Jørgen Elmer, additional, and Nielsen, Xiaohui Chen, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Forhøjede blodcelletal og vaskulær sygdom med de myeloproliferative neoplasier som modelsygdomme
- Author
-
Hasselbalch, Hans Carl, Knudsen, Trine Alma, Sørensen, Anders Lindholm, Friis Christensen, Sarah, Kranker Larsen, Morten, Bak, Marie, El Fassi, Daniel, Cordua, Sabrina, Brabrand, Mette, Thomsen, Gitte, Stentoft, Jesper, Starklint, Jørn, Ellervik, Christina, Wienecke, Troels, Bruun, Niels Eske, Eickhardt-Dalbøge, Christina Schjellerup, Kjær, Lasse, and Skov, Vibe
- Subjects
food and beverages - Abstract
Recent studies have shown the Philadelphia-negative myeloproliferative neoplasms (MPN) to be massively underdiagnosed and often preceded by a long pre-diagnostic phase of several years, in which many patients suffer serious vascular events. In this review, we focus on the urgent need for earlier diagnosis and treatment of MPN. Such efforts are foreseen to decrease morbidity and mortality for the individual patients and potentially reduce costs for health and social care systems.
- Published
- 2021
19. Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN
- Author
-
Knudsen, Trine Alma, Hansen, Dennis Lund, Ocias, Lukas Frans, Bjerrum, Ole, Brabrand, Mette, Christensen, Sarah Friis, Eickhardt-Dalbøge, Christina Schjellerup, Ellervik, Christina, El Fassi, Daniel, Frederiksen, Mikael, Kjær, Lasse, Kristensen, Thomas Kielsgaard, Kruse, Torben A., Larsen, Morten Kranker, Mourits-Andersen, Torben, Möller, Sören, Overgaard, Ulrik Malthe, Severinsen, Marianne Tang, Skov, Vibe, Sørensen, Anders Lindholm, Stentoft, Jesper, Starklint, Jørn, de Stricker, Karin, Thomassen, Mads, Larsen, Thomas S., and Hasselbalch, Hans C.
- Abstract
Background:Hydroxyurea (HU) is the most commonly used first-line cytoreductive treatment option for patients with myeloproliferative neoplasms (MPN) worldwide. However, increasing evidence on the efficacy and safety of pegylated interferon-alpha2 (IFNα) is emerging, and optimal first-line treatment is to be established.
- Published
- 2023
- Full Text
- View/download PDF
20. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
- Author
-
Larsen MK, Skov V, Kjær L, Eickhardt-Dalbøge CS, Knudsen TA, Kristiansen MH, Sørensen AL, Wienecke T, Andersen M, Ottesen JT, Gudmand-Høyer J, Snyder JA, Andersen MP, Torp-Pedersen C, Poulsen HE, Stiehl T, Hasselbalch HC, and Ellervik C
- Subjects
- Humans, Longitudinal Studies, Neutrophils, Lymphocytes, Denmark epidemiology, Myeloproliferative Disorders epidemiology, Polycythemia Vera, Primary Myelofibrosis epidemiology, Thrombocythemia, Essential epidemiology
- Abstract
The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1-1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03-2.09) for the whole population and 2.93(2.44-3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71-2.69), 2.19(1.89-2.54), and 2.31(1.91-2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(p
interaction < 2×10-16 ), with a HR for NLR ≥ 6 of 2.23(2.17-2.29), 4.10(4.01-4.20), and 7.69(7.50-7.89), for CCI-score 0, 1-2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.